Publication: 44

Two or Three Year Disease Free Survival (DFS) as a Primary Endpoint in Stage III Adjuvant Colon Cancer Trials with fluoropyrimidines with or without Oxaliplatin or Irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07, and C89803
      QxMD      Google Scholar   
Citation:
Eur J Cancer vol 47 (7) 990-996
Year:
2011
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Comprehensive
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
Yes
Book Volume:
Parents:
74  
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA025224, U10 CA025224-33, CA-25224  
Corr. Author:
 
Authors:
                       
Networks:
 
Study
Alliance-89803
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
Keywords:
Article